Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer
← catalyst calendarSponsored by GE Healthcare (industry) · GEHC — their whole pipeline →. With Simbec-Orion Group, Keosys.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Diagnostic
Enrollment
153actual
Sites
11
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-02-08 | actual | When the study began enrolling |
| Primary completion | 2025-04-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Breast Cancer
Intervention
- Drug: 18F Fluoroestradiol Radiopharmaceutical with PET/CT — also filed as ESTROTEP
Primary outcome
what the primary-completion date above is the date OFTo assess the impact of ESTROTEP PET/CT on metastatic breast cancer patients management, initially ER+ and HER2-, in relapse after first-line treatment combining hormone therapy.
measured Change from baseline therapeutic measure at 15 days after ESTROTEP PET/CT
Permalink · GEHC's whole pipeline · Catalyst calendar · Every registered study · What changed